Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥13,970 JPY
Change Today +280.00 / 2.05%
Volume 410.7K
4528 On Other Exchanges
As of 2:00 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

ono pharmaceutical co ltd (4528) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - ¥16,800
52 Week Low
10/17/14 - ¥8,650
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONO PHARMACEUTICAL CO LTD (4528)

Related News

No related news articles were found.

ono pharmaceutical co ltd (4528) Related Businessweek News

No Related Businessweek News Found

ono pharmaceutical co ltd (4528) Details

Ono Pharmaceutical Co., Ltd. purchases, produces, and sells pharmaceuticals and diagnostic reagents in Japan, Europe, and Asia. The company offers Rivastach Patch for the treatment of Alzheimer’s disease; Glactiv and FORXIGA tablets to treat type II diabetes; Emend capsules/Proemend intravenous injection for the treatment of chemotherapy-induced nausea and vomiting; Recalbon tablets to treat osteoporosis; Staybla tablets for the treatment of overactive bladder; Opalmon tablets to treat peripheral circulatory disorder; and Onon capsules and dry syrup for the treatment of bronchial asthma and allergic rhinitis. It also provides Kinedak tablets to treat diabetic peripheral neuropathy; Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis; Elaspol injection to treat acute lung injury associated with systemic inflammatory response syndrome; Onoact injection for the treatment of tachyarrhythmia; ORENCIA injection to treat rheumatoid arthritis; and OPDIVO intravenous infusion for treatment of melanoma. In addition, the company develops drugs for small and non-small cell lung, renal cell, head and neck, gastric, urothelial, esophageal, colon, and hematologic cancer; juvenile rheumatoid arthritis; lupus nephritis; multiple myeloma; hyperparathyroidism; ventricular arrhythmia; Hodgkin’s, B cell, diffuse large B cell, and follicular lymphoma; cancer anorexia/cachexia; chronic and acute heart failure; pheochromocytoma; hepatocellular carcinoma; solid tumor; Parkinson’s disease; glioblastoma; irritable bowel syndrome; glaucoma; ocular and portal hypertension; chronic myeloid leukemia; hepatitis C; underactive bladder; and osteoarthritis indications. It has drug discovery alliances with Array BioPharma Inc.; Locus Pharmaceuticals, Inc.; BioSeek LLC; Receptos Inc.; Xention Limited; BioFocus DPI Limited; Evotec AG; Scil Proteins GmbH; Domain Therapeutics S.A.; and Melas. The company was founded in 1717 and is headquartered in Osaka, Japan.

2,913 Employees
Last Reported Date: 06/29/15
Founded in 1717

ono pharmaceutical co ltd (4528) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ono pharmaceutical co ltd (4528) Key Developments

Vodafone Spain-Ono Workers to Strike over Redundancy Plan

Spanish trade union CCOO has called on Vodafone Spain and Ono workers to strike on 21, 28, 29 and 30 September against the collective dismissal of around 1,300 workers as a result of the merger of the two companies. The trade union also called on workers to attend a 19 September demonstration in the centre of Madrid. In a letter sent to employee representatives in July, Vodafone said the redundancies were inevitable due to duplication of work and the fall in revenues and EBITDA of both companies in recent years, added to large investments in next-generation networks. Around 60% of the dismissals will come from Ono (805 workers) with the remaining 40% from Vodafone (492 workers).

Ono Pharmaceutical Co., Ltd. Announces Consolidated Financial Results for the First Quarter Ended June 30, 2015

Ono Pharmaceutical Co., Ltd. announced consolidated financial results for the first quarter ended June 30, 2015. For the quarter, the company reported revenue of ¥35,696 million against ¥31,808 million a year ago. Operating profit was ¥11,674 million against ¥2,777 million a year ago. Profit before tax was ¥13,208 million against ¥3,958 million a year ago. Profit for owners of the parent company was ¥9,453 million or ¥89.17 per basic share against ¥2,908 million or ¥27.43 per basic share a year ago. Profit for the period was ¥9,841 million compared with ¥2,956 million a year ago. Net cash used in operating activities was ¥1,891 million against ¥800 million a year ago. Purchases of property, plant and equipment was ¥566 million against ¥1,609 million a year ago. Purchases of intangible assets were ¥228 million against ¥8,777 million a year ago.

Ono Pharmaceutical Co., Ltd. to Report Q1, 2016 Results on Aug 04, 2015

Ono Pharmaceutical Co., Ltd. announced that they will report Q1, 2016 results on Aug 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4528:JP ¥13,970.00 JPY +280.00

4528 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4528.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4528 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONO PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at